The Natasha Chida Lab investigates methods for using education and curriculum development to improve patient outcomes worldwide, primarily by optimizing education of physicians-in-training. Most recently, our team has worked to develop and evaluate an assessment tool for evaluating internal medicine residents’ understanding of tuberculosis diagnostics. Previous research includes a retrospective cohort study on the high proportion of extrapulmonary TB in a low-prevalence setting as well as an analysis of ways to define clinical excellence in adult infectious disease practice.

Our IndoUS team, based both in Baltimore and in India, specializes in international clinical research (cohort studies and clinical trials), public health implementation science and education in infectious diseases, HIV/AIDS, tuberculosis (TB), vaccine preventable illnesses, antimicrobial resistant infections, and more recently COVID. Since 2003, our work has been focused primarily on India, where we are engaged in several Indo-JHU and international research collaborations. We partner with several leading medical and research institutions in India (e.g. BJGMC, DY Patil, Hinduja Hospital, KEM, Bharati Vidyapeeth, NIRT, JIPMER, CMC, Medanta, IISER, YRG, IIT), as well as others in sub-Saharan Africa, US and Brazil. We are actively involved in the following consortia: 1) Indo-US Vaccine Action Program sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology. 2) RePORT International TB Research Consortium, a multilateral global consortia for TB research, 3) US NIH funded multi-country HIV and TB trials consortia of the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT) Network, 4) NIH and AmFAR funded IeDea HIV/TB Working Group and the Treat Asia-IeDEA HIV and TB epidemiology databases, and 5) CDC SHEPHERD AMR studies. Our group has been awarded research grants from the US NIH, US CDC, UNITAID, Indian government, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond.

The Mihaela Pertea Lab develops computational tools for RNA sequence analysis, gene finding, splice-site prediction and sequence-motif finding. Previous research projects led to the development of open-source software systems related to finding genes.

The nervous system has extremely complex RNA processing regulation. Dysfunction of RNA metabolism has emerged to play crucial roles in multiple neurological diseases. Mutations and pathologies of several RNA-binding proteins are found to be associated with neurodegeneration in both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). An alternative RNA-mediated toxicity arises from microsatellite repeat instability in the human genome. The expanded repeat-containing RNAs could potentially induce neuron toxicity by disrupting protein and RNA homeostasis through various mechanisms. The Sun Lab is interested in deciphering the RNA processing pathways altered by the ALS-causative mutants to uncover the mechanisms of toxicity and molecular basis of cell type-selective vulnerability. Another major focus of the group is to identify small molecule and genetic inhibitors of neuron toxic factors using various high-throughput screening platforms. Finally, we are also highly interested in developing novel CRISPR technique-based therapeutic strategies. We seek to translate the mechanistic findings at molecular level to therapeutic target development to advance treatment options against neurodegenerative diseases.

The Stivers Lab is broadly interested in the biology of the RNA base uracil when it is present in DNA. Our work involves structural and biophysical studies of uracil recognition by DNA repair enzymes, the central role of uracil in adapative and innate immunity, and the function of uracil in antifolate and fluoropyrimidine chemotherapy. We use a wide breadth of structural, chemical, genetic and biophysical approaches that provide a fundamental understanding of molecular function. Our long-range goal is to use this understanding to design novel small molecules that alter biological pathways within a cellular environment. One approach we are developing is the high-throughput synthesis and screening of small molecule libraries directed at important targets in cancer and HIV-1 pathogenesis.

Research in the Salzberg Lab focuses on the development of new computational methods for analysis of DNA from the latest sequencing technologies. Over the years, we have developed and applied software to many problems in gene finding, genome assembly, comparative genomics, evolutionary genomics and sequencing technology itself. Our current work emphasizes analysis of DNA and RNA sequenced with next-generation technology.

The Fukunaga Lab uses multidisciplinary approaches to understand the cell biology, biogenesis and function of small silencing RNAs from the atomic to the organismal level. The lab studies how small silencing RNAs, including microRNAs (miRNAs), small interfering RNAs (siRNAs) and piwi-interacting RNAs (piRNAs), are produced and how they function. Mutations in the small RNA genes or in the genes involved in the RNA pathways cause many diseases, including cancers. We use a combination of biochemistry, biophysics, fly genetics, cell culture, X-ray crystallography and next-generation sequencing to answer fundamental biological questions and also potentially lead to therapeutic applications to human diseases.

Investigators in the Robert Brodsky Lab study normal and abnormal hematopoiesis, particularly mutations of the phosphatidylinositol glycan anchor biosynthesis class A (PIG-A) gene in aplastic anemia. Our team has developed a new diagnostic assay for paroxysmal nocturnal hemoglobinuria (PNH) that is based on the toxin Aaeromonas hydrophila.

The Gail Geller Lab primarily conducts empirical quantitative and qualitative research on the ethical and social implications of genetic testing in the adult, pediatric and family contexts. We have focused on clinical-patient communication under conditions of uncertainty; professionalism and humanism in medical education; cross-cultural variation in concepts of health and disease; and clinician suffering and moral distress. We explore these topics in a range of health care contexts, including genomics, complementary and alternative medicine (CAM) and palliative care. Our researchers have a longstanding interest in medical socialization, provider-patient communication under conditions of uncertainty and cultural differences in attitudes toward health and disease. We also explore the intersection of CAM and bioethics, as well as the role of palliative care in chronic diseases, such as muscular dystrophy and sickle cell disease.

Work in the Green Lab is centered on the ribosome. The overall fidelity of protein synthesis appears to be limited by the action of the ribosome, which is the two-subunit macromolecular machine responsible for decoding and translating messenger RNAs (mRNAs) into protein in all organisms. Our work is divided into four general project areas. The longest-standing research area concerns the interactions of eubacterial ribosomes and release factors. The goal is to understand the mechanism of action of release factors on the ribosome. A second research area involves biochemical and structure/function studies of the miRNA pathway, particularly the mechanism of action of the Argonaute proteins and their interacting factors. A third area of work in the lab is centered around regulation of eukaryotic translation, specifically in understanding the mechanism behind various mRNA quality control pathways and the interactions of proteins therein, as well as with the ribosome. The newest area of research in the lab extends our strengths in ribosome biochemistry to characterize the translation status of the cell using the ribosome profiling. We are using this technique to better understand the role of several factors involved in eukaryotic and prokaryotic translation fidelity.